首页>投融资
UCB
收并购
UCB Pharma is a subsidiary of UCB SA. By November 2005, UCB Pharma employed over 3000 people worldwide and conducted research in the fields of central nervous system (CNS) disorders, including epilepsy, cardiovascular diseases and immunoallergology. It also had a biotechnology company, UCB-Bioproducts, which researched peptides and peptidomimetics with potential therapeutic utility.In January 2000, UCB Pharma acquired the pharmaceutical division of Fujirebio.In October 1999, UCB was involved in the formation of a new company based in France, Genfit SA, which was to provide a technology platform in the area of functional genomics
基本信息
-
公司全称UCB Pharma SA
-
类型生物制药和特种化学品开发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数500人以上
-
地址Allee de la Recherche, 60 BRUXELLES BRUXELLES-CAPITALE 1070; BE; Telephone: +3225599220; Fax: +3225599009;
-
联系电话3225599220
-
邮箱Luc.Vermeesch@UCB-Group.com
-
成立时间1928-01-01
投融资
-
2024-11-30收并购6.8亿美元Mubadala康桥资本
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息